Cumberland Pharmaceuticals Inc. (CPIX)

NASDAQ: CPIX · IEX Real-Time Price · USD
1.680
-0.110 (-6.15%)
Mar 28, 2024, 4:30 PM EDT - Market closed

Company Description

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally.

The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis.

In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension.

Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases.

The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals logo
Country United States
IPO Date Aug 11, 2009
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 91
CEO A. J. Kazimi MBA

Contact Details

Address:
2525 West End Avenue, Suite 950
Nashville,, Tennessee 37203
United States
Phone 615-255-0068
Website cumberlandpharma.com

Stock Details

Ticker Symbol CPIX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001087294
CUSIP Number 230770109
ISIN Number US2307701092
SIC Code 2834

Key Executives

Name Position
A. J. Kazimi MBA Founder, Chairman, President and Chief Executive Officer
John Michael Hamm Vice President and Chief Financial Officer
James Lowrance Herman Executive Vice President of National Accounts and Chief Compliance Officer
Chris T. Bitterman Vice President of Sales and Marketing
Todd M. Anthony Vice President of Organizational Development
Jean W. Marstiller Senior Vice President of Administrative Services and Corporate Secretary
Adam S. Mostafa Managing Director
Erin Smith Gull Senior Corporate Relations Associate

Latest SEC Filings

Date Type Title
Mar 22, 2024 ARS Filing
Mar 20, 2024 8-K Current Report
Mar 20, 2024 424B5 Filing
Mar 13, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 13, 2024 DEF 14A Other definitive proxy statements
Mar 13, 2024 10-K Annual Report
Mar 5, 2024 8-K Current Report
Feb 9, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Dec 26, 2023 EFFECT Notice of Effectiveness
Dec 15, 2023 DEL AM Filing